Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/202134
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.
Matèries
Matèries (anglès)
Citació
Citació
LÓPEZ CAMPOS, Fernando, GAJATE, Pablo, ROMERO LAORDEN, Nuria, ZAFRA MARTÍN, Juan, JUAN, Manel, HERNANDO POLO, Susana, CONDE MORENO, Antonio, COUÑAGO, Felipe. Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. _Biomedicines_. 2022. Vol. 10, núm. 3. [consulta: 23 de gener de 2026]. ISSN: 2227-9059. [Disponible a: https://hdl.handle.net/2445/202134]